Maxcyte (MXCT) Receivables (2020 - 2026)

Maxcyte (MXCT) has 7 years of Receivables data on file, last reported at $4.2 million in Q1 2026.

• On a quarterly basis, Receivables fell 23.15% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 23.15% decrease from a year earlier, with the FY2025 full-year figure at $3.5 million, down 25.18% from the prior year.
• Receivables for Q1 2026 stood at $4.2 million, up from $3.5 million in the prior quarter.
• Over the last five years, Receivables for MXCT reached as high as $11.2 million in Q4 2022 and fell as low as $3.5 million in Q4 2025.
• Historically, Receivables has averaged $6.6 million across 5 years, with a median of $6.0 million in 2024.
• Across the five-year window, Receivables tumbled 48.3% in 2023 and jumped 82.15% in 2025, its largest moves.
• Year by year, Receivables stood at $11.2 million in 2022, then sank by 48.3% to $5.8 million in 2023, then decreased by 18.97% to $4.7 million in 2024, then decreased by 25.18% to $3.5 million in 2025, then grew by 21.21% to $4.2 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $4.2 million in Q1 2026, $3.5 million in Q4 2025, and $8.3 million in Q3 2025.